You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A simple assay system for rapid detection of circulating tumor cells
SBC: TELOVISION, LLC Topic: NCIDESCRIPTION provided by applicant Metastasis or dissemination of primary tumor cells is the major cause of mortality in cancer patients Circulating tumor cells CTCs in the bloodstream are key players in the establishment of metastatic tumors Recent studies demonstrated that the number of CTCs present in patient blood directly correlate with cancer progression recurrence and survival rate ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of Peptide Antibiotic Nucleic Acids
SBC: NUBAD LLC Topic: NIAIDDESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Silica Colloidal Crystals for High Resolution MALDI-MS of Glycoproteins
SBC: LI-COR, Inc. Topic: 100DESCRIPTION provided by applicant The product is a slide coated with silica colloidal crystals to combine protein electrophoresis with matrix assisted laser desorption ionization mass spectrometry MALDI MS detection giving superior performance in both The Phase II proposal will be to develop an instrument for facile application of the slide in proteomics of intat glycoproteins This propos ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Metal ion-functionalized soluble nanopolymers: A new analytical platform for plas
SBC: TYMORA ANALYTICAL OPERATIONS LLC Topic: 300DESCRIPTION provided by applicant Mass spectrometry based proteomics is an emerging technology that has seen possible applications everywhere The technique can potentially use one drop of our blood to reveal onset and progress of diseases Current Randamp D using plasma serum proteome sample sets however is severely limited by the high complexity and dynamic range of protein concentrations ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Universal amplifier system for high-fidelity multi-modal biosignal recordings
SBC: REFER2INPUT, LLC Topic: 213DESCRIPTION provided by applicant The measurement monitoring and use of bioelectric signals has evolved from the measurement of the electrical activity of the heart to encompass tissues ranging from cardiac skeletal and smooth muscles to brain and peripheral nerve tissues Together with this development has been the evolution of specialized equipment to capture and interpret these minute sig ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Next Generation Semiconductor-Based Radiation Detectors Using Cadmium Magnesium Telluride
SBC: BRIMROSE TECHNOLOGY CORP Topic: 23cAt present, CdZnTe is considered the material of choice for efficient, room temperature gamma-radiation detection systems used for the detection and identification of radionuclides. Despite the advances in CdZnTe materials technology during the last decade, the major impediments in the progress of - ray detection technology are the low yield of device quality materials and detectors, and the limit ...
STTR Phase I 2014 Department of Energy -
Development of VPL Vaccine for RSV
SBC: SIGMOVIR BIOSYSTEMS, INC. Topic: NIAIDProject Summary Human respiratory syncytial virus (RSV) is recognized as the single most important viral cause of acute respiratory disease in infants and young children worldwide. Elderly populations and immunocompromised individuals are also at significant risk for serious RSV disease. Despite this very substantial disease burden imposed by RSV worldwide, there are no vaccines available. Severa ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics
SBC: PPI PHARMACEUTICALS, LLC Topic: NCIDESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Developing a Nrf2 activator for the treatment of scleroderma
SBC: CUREVEDA, LLC Topic: NIAMSDESCRIPTION (provided by applicant): Scleroderma is a devastating autoimmune disease with a chronic course, involving the overproduction of collagen leading to fibrosis of the skin and connective tissues. The disease has a range of symptoms including pain,stiffness and swelling of the joints, shortness of breath and gastrointestinal complications. More than 50% of patients with the aggressive form ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Mucins in the Diagnosis and Prognosis of Pancreatic Diseases
SBC: Sanguine Diagnostics And Therapeutics, Inc. Topic: NCIDESCRIPTION (provided by applicant): Due to its asymptomatic nature and lack of methods for early detection, gt 80% of pancreatic cancer (PC) patients present with an unresectable primary tumor with distant metastasis at the time of diagnosis. While the overall 5 year survival rate of pancreatic cancer is dismal, significantly better outcomes have been reported for smaller tumors detected at an e ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health